Defendant
1 case as defendant.
Gene Logic, Inc. was a functional-genomics company founded in 1994 in Gaithersburg, Maryland, where it kept its headquarters (50 West Watkins Mill Road). It began R&D in 1996, went public in 1997, and traded on NASDAQ under the ticker GLGC. It later maintained operations in Cambridge, Massachusetts. Size figures are not reliably documented in public sources; one business-directory listing cites a 250–1,000 employee band, but that is uncorroborated and should be treated as approximate.
Products and operations. Gene Logic sold molecular-bioinformatics databases and services to pharmaceutical and diagnostic customers. Its principal offerings were the BioExpress and ToxExpress gene-expression and toxicogenomics databases, the Genesis Enterprise System bioinformatics software, and microarray data-generation and analysis services; the company also ran preclinical contract-research services and a molecular diagnostics unit. From roughly 2006 it repositioned itself as a drug-repositioning and development company, and its lead internal candidate was GL1001, a small molecule for inflammatory bowel disease. This was an operating company, not a patent-assertion entity.
Ownership history. In October 2007 Gene Logic agreed to sell its genomics assets (databases, Genesis software, microarray services) to Hyderabad-based Ocimum Biosolutions for $10 million; the Gene Logic name went with that business. The remaining company renamed itself Ore Pharmaceuticals Inc. (ORXE). Ocimum was later backed by an up-to-$17 million investment from The Kubera Cross-Border Fund. Control of the Gene Logic name and genomics assets therefore rests with Ocimum, not with the original public entity.
Patent-litigation posture. Gene Logic appears in the tracked data only as a defendant, in a single case: Incyte Genomics, Inc. v. Gene Logic, Inc., in the U.S. District Court for the Northern District of California — zero plaintiff cases. This is the profile of an operating company defending against another operating company's patents, not an NPE. Notably, the suit was not filed in a plaintiff-friendly venue such as the Eastern District of Texas.
Case context. Incyte filed in December 1999 and again in August 2000, asserting U.S. Patents 5,716,785 and 5,891,636 (non-PCR RNA amplification) and 6,023,659 (a biomolecular-sequence database system), with Gene Logic filing counterclaims. The parties settled under a license agreement granting Gene Logic non-exclusive rights to the asserted patents and to U.S. Patent 5,807,522 (microarray fabrication).
Incyte Genomics, Inc., as exclusive licensee of Stanford's patents, sued Gene Logic, Inc. for infringement in the Northern District of California. The case asserted U.S. 5,716,785, U.S. 5,891,636, and U.S. 6,023,659. It settled in January 2001, the lawsuits were dismissed, and Gene Logic received a non-exclusive license.